The effect of renal disease on the disposition of venlafaxine
1994; Wiley; Volume: 56; Issue: 1 Linguagem: Inglês
10.1038/clpt.1994.95
ISSN1532-6535
AutoresSteven Troy, Robert W. Schultz, Vernon D. Parker, Soong T. Chiang, Robert A. Blum,
Tópico(s)Hemodynamic Monitoring and Therapy
ResumoClinical Pharmacology & TherapeuticsVolume 56, Issue 1 p. 14-21 Pharmacokinetics and Drug Disposition The effect of renal disease on the disposition of venlafaxine Steven M Troy MS, Steven M Troy MS Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorRobert W Schultz MD, Robert W Schultz MD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorVernon D Parker PhD, Vernon D Parker PhD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorSoong T Chiang PhD, Soong T Chiang PhD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorRobert A Blum PharmD, Corresponding Author Robert A Blum PharmD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorRobert A Blum, PharmD, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY, 14209-1194.Search for more papers by this author Steven M Troy MS, Steven M Troy MS Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorRobert W Schultz MD, Robert W Schultz MD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorVernon D Parker PhD, Vernon D Parker PhD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorSoong T Chiang PhD, Soong T Chiang PhD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorSearch for more papers by this authorRobert A Blum PharmD, Corresponding Author Robert A Blum PharmD Clinical Pharmacokinetics Laboratory, Department of Medicine, Millard Fillmore Hospital Center for Clinical Pharmacy Research, State University of New York at Buffalo, Buffalo Wyeth-Ayerst, RadnorRobert A Blum, PharmD, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY, 14209-1194.Search for more papers by this author First published: July 1994 https://doi.org/10.1038/clpt.1994.95Citations: 18AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract The pharmacokinetics of venlafaxine and its active metabolite O-desmethylvenlafaxine were studied in subjects with various degrees of renal dysfunction, including subjects requiring maintenance hemodialysis. Venlafaxine was administered as a single 50 mg dose, with blood and urine samples obtained at intervals up to 48 hours after administration for the subjects receiving dialysis or 72 hours for the subjects not receiving dialysis. Six subjects receiving dialysis also completed an intradialysis evaluation to estimate dialysis clearance. Concentrations of venlafaxine and O-desmethylvenlafaxine in plasma, urine, and dialysate fluid were determined by high-performance liquid chromatography. Apparent total clearance of venlafaxine and O-desmethylvenlafaxine were both significantly decreased by approximately 55% in the subjects receiving dialysis, and terminal disposition half-life was significantly prolonged for both compounds. Venlafaxine and O-desmethylvenlafaxine are poorly dialyzable. In conclusion, the disposition of venlafaxine and O-desmethylvenlafaxine is markedly altered in renal disease; therefore dosage adjustment is warranted for patients with creatinine clearance values below 30 ml/min. Clinical Pharmacology and Therapeutics (1994) 56, 14–21; doi:10.1038/clpt.1994.95 Citing Literature Volume56, Issue1July 1994Pages 14-21 RelatedInformation
Referência(s)